SILENCE THERAPEUTICS PLC-ADR

SLN represents the common stock of Silence Therapeutics plc, a biopharmaceutical company. It trades on the Nasdaq Global Market as an American Depositary Share. SLN gives investors exposure to a clinical-stage RNA interference company focused on developing therapies for cardiovascular, hematologic, and other diseases. Its value is tied to pipeline progress and regulatory outcomes rather than commercial product sales.

SLN operates in the biotechnology and pharmaceuticals industry, specifically in RNA interference (RNAi) therapeutics. The company develops medicines designed to silence specific genes that cause disease. This places SLN within the broader healthcare sector, where research and development spending, clinical trial results, and regulatory approvals are key drivers of business performance.

The 52-week range shows the lowest and highest prices at which SLN has traded over the past year. Because this range changes with market activity, the current figures are not included here. You can find the latest 52-week high and low for SLN on the stock detail page displayed with the price chart.

SLN is a clinical-stage biotech company, so it may not currently generate positive earnings. A price-to-earnings ratio requires positive earnings per share to be meaningful. As a result, the P/E ratio may not be available or relevant for SLN. Investors often look at other metrics, such as cash position and pipeline progress, when evaluating the company.

SLN may be eligible for extended-hours trading through some brokers, but liquidity is typically lower than during the regular Nasdaq session. Trading outside regular hours can involve wider spreads and greater price volatility. Availability depends on your brokerage and the venue. Check your broker's extended-hours rules and the latest SLN quote before attempting such trades.

Clinical-stage biotech companies like SLN face significant risks, including the possibility that drug candidates fail in trials, regulatory delays, and competition from other therapies. SLN may also need additional financing, which could dilute existing shareholders. Because the company may not have approved products generating revenue, its stock can be highly volatile and sensitive to pipeline news.